HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Keros Therapeutics (NASDAQ:KROS) and maintained a $100 price target.
August 09, 2023 | 10:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Keros Therapeutics (NASDAQ:KROS) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $100.
The reiteration of a 'Buy' rating and a maintained price target of $100 by HC Wainwright & Co. indicates a positive outlook for Keros Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100